$512.70▴ 0.45%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
Fair value
Undervalued
Trading about 38% below our fair-value range
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
United Therapeutics Corporation's earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days1 article
0 bullish1 neutral0 bearish
LIQUIDIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Liquidia Corporation on Behalf of Liquidia Stockholders and Encourages Investors to Contact the Firm
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now?
FDA Accepts UTHR's sNDA for Tyvaso in Idiopathic Pulmonary Fibrosis- Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition?
- FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH